Cost-utility analysis of selective internal radiation therapy with Y-90 resin microspheres in hepatocellular carcinoma. Muszbek, N., Remák, E., Evans, R., Brennan, V., Colaone, F., Shergill, S., Mullan, D., & Ross, P. Future Oncology (London, England), 17(9):1055–1068, March, 2021.
doi  abstract   bibtex   
Background: The study assessed the cost-utility of selective internal radiation therapy (SIRT) with Y-90 resin microspheres versus sorafenib in UK patients with unresectable hepatocellular carcinoma ineligible for transarterial chemoembolization. Materials & methods: A lifetime partitioned survival model was developed for patients with low tumor burden (≤25%) and good liver function (albumin-bilirubin grade 1). Efficacy, safety and quality of life data were from a European Phase III randomized controlled trial and published studies. Resource use was from registries and clinical surveys. Results: Discounted quality-adjusted life-years were 1.982 and 1.381, and discounted total costs were £29,143 and 30,927, for SIRT and sorafenib, respectively. Conclusion: SIRT has the potential to be a dominant (more efficacious/less costly) or cost-effective alternative to sorafenib in patients with unresectable hepatocellular carcinoma.
@article{muszbek_cost-utility_2021,
	title = {Cost-utility analysis of selective internal radiation therapy with {Y}-90 resin microspheres in hepatocellular carcinoma},
	volume = {17},
	issn = {1744-8301},
	doi = {10.2217/fon-2020-1004},
	abstract = {Background: The study assessed the cost-utility of selective internal radiation therapy (SIRT) with Y-90 resin microspheres versus sorafenib in UK patients with unresectable hepatocellular carcinoma ineligible for transarterial chemoembolization. Materials \& methods: A lifetime partitioned survival model was developed for patients with low tumor burden (≤25\%) and good liver function (albumin-bilirubin grade 1). Efficacy, safety and quality of life data were from a European Phase III randomized controlled trial and published studies. Resource use was from registries and clinical surveys. Results: Discounted quality-adjusted life-years were 1.982 and 1.381, and discounted total costs were £29,143 and 30,927, for SIRT and sorafenib, respectively. Conclusion: SIRT has the potential to be a dominant (more efficacious/less costly) or cost-effective alternative to sorafenib in patients with unresectable hepatocellular carcinoma.},
	language = {eng},
	number = {9},
	journal = {Future Oncology (London, England)},
	author = {Muszbek, N. and Remák, E. and Evans, R. and Brennan, V.K. and Colaone, F. and Shergill, S. and Mullan, D. and Ross, P.J.},
	month = mar,
	year = {2021},
	keywords = {cost–effectiveness, decision models, hepatocellular carcinoma, microspheres},
	pages = {1055--1068},
}

Downloads: 0